Bright Minds Biosciences Inc.

CNSX:DRUG Stock Report

Market Cap: CA$379.0m

Bright Minds Biosciences Management

Management criteria checks 2/4

Bright Minds Biosciences' CEO is Ian McDonald, appointed in May 2019, has a tenure of 5.58 years. directly owns 14.03% of the company’s shares, worth CA$53.17M. The average tenure of the management team and the board of directors is 2.4 years and 2.6 years respectively.

Key information

Ian McDonald

Chief executive officer

CA$626.2k

Total compensation

CEO salary percentagen/a
CEO tenure5.6yrs
CEO ownership14.0%
Management average tenure2.4yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Oct 16
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19
Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07
We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04
We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

CEO

Ian McDonald (36 yo)

5.6yrs

Tenure

CA$626,178

Compensation

Mr. Ian McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executive Officer since June 06, 2020 and serves as its President and Director since May 31, 2019. He served as Presi...

Leadership Team

NamePositionTenureCompensationOwnership
Ian McDonald
Co-Founder5.6yrsCA$626.18k14.03%
CA$ 53.2m
Ryan E. S. Cheung
Chief Financial Officer4.6yrsCA$120.00k0%
CA$ 0
Jan Pedersen
Chief Science Officer & Director2.3yrsCA$799.72k0.50%
CA$ 1.9m
Mark Smith
Chief Medical Officer2yrsCA$505.51kno data
Alex Vasilkevich
COO & VP of Corporate Developmentless than a yearno data0.28%
CA$ 1.1m
Emer Leahy
Consultant2.6yrsno datano data

2.4yrs

Average Tenure

58yo

Average Age

Experienced Management: DRUG's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ian McDonald
Co-Founder5.6yrsCA$626.18k14.03%
CA$ 53.2m
Jan Pedersen
Chief Science Officer & Director2.7yrsCA$799.72k0.50%
CA$ 1.9m
Robert Malenka
Member of Scientific Advisory Board2.6yrsno datano data
Herbert Meltzer
Member of Scientific Advisory Board2.6yrsno datano data
David Weiner
Independent Non-Executive Director1.8yrsCA$22.04kno data
Jeremy Fryzuk
Independent Director4.3yrsCA$7.69k2.79%
CA$ 10.6m
Nils Bottler
Independent Director4.3yrsCA$7.69k0.072%
CA$ 272.7k
Michael Bogenschutz
Member of Scientific Advisory Board2.6yrsno datano data
Peter Hendricks
Member of Scientific Advisory Board2.6yrsno datano data

2.6yrs

Average Tenure

39yo

Average Age

Experienced Board: DRUG's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bright Minds Biosciences Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Sepehr ManochehryEight Capital